Literature DB >> 26792138

A retrospective research of HIV-negative cryptococcal meningoencephalitis patients with acute/subacute onset.

H Zheng1, Q Chen1, Z Xie1, D Wang1, M Li2, X Zhang1, Y Man1, J Lao3, N Chen3, L Zhou4.   

Abstract

Cryptococcal meningoencephalitis (CM) may present as an acute, subacute, or chronic infection. It manifests as a chronic process in over 75 % of cases, but, sometimes, it presents with a more acute onset, mostly in HIV-associated patients. Until now, there has been no study performed on the clinical features of HIV-negative CM patients with acute/subacute onset. We collected 106 HIV-negative patients diagnosed with CM in our hospital during a 15-year period, analyzed their epidemiological and clinical features, as well as the outcomes, and explored the independent prognosis factors and the factors related to the survival time among them. We found that impaired consciousness (23.4 % vs. 3.4 %, p = 0.017) was more common in CM patients with acute/subacute onset, while decreased cerebrospinal fluid (CSF) glucose (51.9 % vs. 75.9 %, p = 0.026) was less common. The ratio of CSF glucose/blood glucose [odds ratio (OR) 0.04, 95 % confidence interval (CI) 0.004-0.262, p = 0.02], impaired consciousness (OR 5.09, 95 % CI 1.477-17.522, p = 0.01), and hospitalization length (OR 0.98, 95 % CI 0.977-0.999, p = 0.04) were indicated to be not only independent prognosis factors in HIV-negative CM patients with acute/subacute onset, but also factors significantly related to the survival time. The results of our study demonstrated that the contact history and potential history risk factors would not affect the onset process of HIV-negative CM patients, and the mortality, hospitalization length, and survival time has not been related to the onset process. However, the ratio of CSF glucose/blood glucose, consciousness level, and hospitalization length of the HIV-negative CM patients with acute/subacute onset should be of greater focus in the clinical work.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26792138     DOI: 10.1007/s10096-015-2545-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  19 in total

1.  Prognostic markers in AIDS-related cryptococcal meningitis.

Authors:  S Majumder; S K Mandal; D Bandyopadhyay
Journal:  J Assoc Physicians India       Date:  2011-03

2.  Evidence behind the WHO guidelines: hospital care for children: what is the most appropriate anti-fungal treatment for acute cryptococcal meningitis in children with HIV?

Authors:  Yamikani Chimalizeni; David Tickell; Tom Connell
Journal:  J Trop Pediatr       Date:  2010-02       Impact factor: 1.165

3.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

4.  [Prognosis factors in cryptococcal meningoencephalitis].

Authors:  C Darzé; R Lucena; I Gomes; A Melo
Journal:  Arq Neuropsiquiatr       Date:  1999-09       Impact factor: 1.420

5.  Cryptococcosis in China (1985-2010): review of cases from Chinese database.

Authors:  Chen Yuchong; Che Fubin; Chen Jianghan; Wei Fenglian; Xu Nan; Yang Minghui; Sun Yalin; Zheng Zhizhong
Journal:  Mycopathologia       Date:  2011-10-07       Impact factor: 2.574

Review 6.  Chronic and subacute meningitis.

Authors:  Joseph R Zunt; Kelly J Baldwin
Journal:  Continuum (Minneap Minn)       Date:  2012-12

7.  Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing.

Authors:  M D Witt; R J Lewis; R A Larsen; E N Milefchik; M A Leal; R H Haubrich; J A Richie; J E Edwards; M A Ghannoum
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

Review 8.  Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.

Authors:  Derek Sloan; Sipho Dlamini; Navin Paul; Martin Dedicoat
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

9.  Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.

Authors:  Peter G Pappas; Beatriz Bustamante; Eduardo Ticona; Richard J Hamill; Philip C Johnson; Annette Reboli; Judith Aberg; Rodrigo Hasbun; Henry H Hsu
Journal:  J Infect Dis       Date:  2004-05-24       Impact factor: 5.226

10.  A retrospective study of contributing factors for prognosis and survival length of cryptococcal meningoencephalitis in Southern part of China (1998-2013).

Authors:  Hui Zheng; Mingyue Li; Yingting Luo; Dongmei Wang; Jialing Yang; Qiong Chen; Junying Lao; Ningfen Chen; Man Yang; Qun Wang
Journal:  BMC Infect Dis       Date:  2015-02-19       Impact factor: 3.090

View more
  2 in total

1.  Acute versus subacute community-acquired meningitis: Analysis of 611 patients.

Authors:  Tarek Sulaiman; Lucrecia Salazar; Rodrigo Hasbun
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

Review 2.  Central Nervous System Cryptococcal Infections in Non-HIV Infected Patients.

Authors:  Justin Beardsley; Tania C Sorrell; Sharon C-A Chen
Journal:  J Fungi (Basel)       Date:  2019-08-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.